STOCK TITAN

Organicell Regenerative Medicine Inc - OCEL STOCK NEWS

Welcome to our dedicated news page for Organicell Regenerative Medicine (Ticker: OCEL), a resource for investors and traders seeking the latest updates and insights on Organicell Regenerative Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Organicell Regenerative Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Organicell Regenerative Medicine's position in the market.

Rhea-AI Summary
Leading Therapeutics Research Company, ZEO ScientifiX, Inc. (formerly Organicell Regenerative Medicine, Inc.), announced a corporate action changing its name to ZEO ScientifiX, Inc. and its stock trading symbol from OCEL to ZEOX. The common stock will now trade on OTCQB starting March 5, 2024, with no change in the CUSIP number. CEO Harry Leider expressed excitement about this new era.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Leading Therapeutics Research Company, ZEO ScientifiX, Inc. (formerly Organicell Regenerative Medicine, Inc.), announced a corporate action changing its name to ZEO ScientifiX, Inc. and its stock trading symbol from OCEL to ZEOX. The common stock will now trade on OTCQB starting March 5, 2024, with no change in the CUSIP number. CEO Harry Leider expressed excitement about this new era.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Organicell Regenerative Medicine Inc (OCEL) announced a 1-for-200 Reverse Split of the Company's common stock effective November 27, 2023. This strategy aims to reduce the number of outstanding shares, improve marketability, and liquidity, maximize valuation, and attract potential investors, particularly institutional and international investors. The Company's common stock will begin trading on a post-Reverse Split basis on November 28, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.26%
Tags
clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.5%
Tags
covid-19
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.33%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
Organicell Regenerative Medicine Inc

OTC:OCEL

OCEL Rankings

OCEL Stock Data

16.85M
3.60M
59.16%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Fort Lauderdale

About OCEL

organicell regenerative medicine, inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the united states. the company was formerly known as biotech products services and research, inc. and changed its name to organicell regenerative medicine, inc. in june 2018. organicell regenerative medicine, inc. has an agreement with regenerative care network to study potential therapeutic benefits of zofin for patients with heart failure. organicell regenerative medicine, inc. was founded in 2011 and is headquartered in miami, florida.